Document Classification

Section Type: RESULTS

Text: Compared with the placebo group, the natalizumab group exhibited significant decreases in : (i) the proportion of patients with new Gd enhancing lesions that evolved to T1-hypointense lesions (10/38 [26 %] versus 27/40 [68 %] ; p < 0. 01) ; (ii) the proportion of patients who developed large T1 hypointense lesions (2/38 [5 %] versus 16/40 [40 %] ; p < 0. 01) ; (iii) the proportion of new Gd enhancing lesions that became T1 hypointense (11/75 [15 %] versus 118/466 [25 %] ; p = 0. 045) ; (iv) the mean proportion per patient of new Gd enhancing lesions that converted to T1-hypointense lesions (0. 15 versus 0. 28 ; p = 0. 005), and (v) the odds ratio (OR) of converting from Gd enhancing to T1-hypointense lesions (OR = 0. 48 ; 95 % CI = 0. 24, 0. 94, p = 0. 031).